Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SAGE | Common Stock | Award | $0 | +11.3K | +80.76% | $0.00 | 25.2K | Feb 13, 2024 | Direct | F1, F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SAGE | Stock Option (Right to Buy) | Award | $0 | +22.5K | $0.00 | 22.5K | Feb 13, 2024 | Common Stock | 22.5K | $23.02 | Direct | F3 |
Id | Content |
---|---|
F1 | Consists of shares of common stock issuable under 11,250 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on February 13, 2025. |
F2 | Reflects beneficial ownership balance which includes 215 shares purchased on December 29, 2023 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan. |
F3 | The securities awarded on February 13, 2024 were in the form of stock options issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. Options to purchase 5,625 shares of common stock shall vest on the one year anniversary of February 13, 2024, with 16,875 shares vesting in 36 equal monthly installments thereafter. |